US FDA Investigating Auto-Injector Problems With Copaxone Generics
Executive Summary
Reports of bent needles and injector failures also raise questions about the FDA’s complex product approval process.
You may also be interested in...
US FDA’s New Generics Chief: We Need More Flexibility For Complex Products
Iilun Murphy said Hatch-Waxman was written with immediate-release oral drugs in mind, not the complex generics becoming more popular today. The agency is evaluating the issue.
Viatris Sues Teva In US Over ‘Illegal Copaxone Scheme’
Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.
FDA Considers Incorporating Patient Input In Generic Drug Assessments
The popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.